Buy Adakveo (crizanlizumab) Online For Sale

Description

Adakveo (crizanlizumab) is the first targeted therapy that has been approved for managing sickle cell disease. It is used to reduce the frequency of vaso-occlusive crises, also known as painful crises, in patients aged 16 years and older who are diagnosed with sickle cell disease.

Sickle cell disease is a serious genetic condition that affects the production of normal hemoglobin, which in turn affects the shape of red blood cells. This causes them to become sickle-shaped, leading to blockages in the small blood vessels resulting in vaso-occlusive crises, severe pain, and organ damage. It can also lead to other complications such as infections, chronic pain, and anemia.

Adakveo works by blocking the interaction between endothelin-1 and P-selectin, which is responsible for the adhesion of sickle red blood cells to the endothelium in the blood vessels. This mechanism helps reduce the frequency and duration of vaso-occlusive crises, leading to improved quality of life for sickle cell patients.

The effectiveness of Adakveo was demonstrated in clinical trials involving over 400 patients with sickle cell disease. Results showed that patients who received Adakveo had a significantly lower rate of vaso-occlusive crises and fewer hospitalizations compared to patients who received a placebo.

The use of Adakveo is not recommended for treating acute vaso-occlusive crises as it is designed to prevent them from occurring. The medication is administered by intravenous infusion every four weeks under the supervision of qualified healthcare professionals.

Common side effects of Adakveo include nausea, joint pain, and back pain. Patients may also experience infusion-related reactions such as fever, chills, and fatigue. However, these side effects are mild to moderate in nature and usually don’t require the discontinuation of the medication.

In conclusion, Adakveo (crizanlizumab) is an innovative medication that represents a breakthrough for the treatment of sickle cell disease, which is a genetic disorder that affects millions of people worldwide. Approved by the FDA in November 2019, Adakveo is the first targeted therapy designed to reduce the frequency and duration of vaso-occlusive crises in patients with sickle cell disease aged 16 years and older. The medication works by blocking the interaction between endothelin-1 and P-selectin in the blood vessels, leading to fewer painful crises and improved quality of life for patients. Although rare, severe adverse reactions may occur, and it is essential to consult a qualified healthcare professional before starting or stopping Adakveo treatment. Adakveo is a much-needed treatment option for sickle cell patients and provides hope for a brighter future for them.